Key facts
- Regatta Bio’s last known valuation is $5.0M (Dec 2024).
- It has raised $1.4M; the latest was Grant ($80K) in May 2025.
- Notable investors include Harvard Innovation Launch Lab, Eos BioInnovation, Panacea Capital (California).
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Regatta Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Regatta Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Regatta Bio
Developer of regulatory T cell (Treg) therapies for transplantation and immune-related conditions. The company's Treg-based therapies aim to treat immune-mediated disorders including chronic graft-versus-host disease (cGvHD), solid organ rejection, autoimmune diseases, and inflammatory disorders by addressing the shortcomings of conventional immunosuppressive treatments, enabling the immunotherapy market to provide targeted, durable, and safer immune regulation that improves patient outcomes while minimizing side effects.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2024
- Employees
- 2
- Website
- regatta.bio/
- Ownership
- Privately Held (backing)
Regatta Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Regatta Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Regatta Bio in its N-PORT filings yet. We sweep new filings monthly.